A couple of decades ago, talking about mental health issues in the public was an unspoken taboo. Research on mental health conditions hadn’t come as far as today, and society’s view of mental health wasn’t as open, which led to many people suffering in silence, scared to speak up or seek help. Today discussing how conditions are approached and treated is much more open.
Among the most common mental health conditions is depression, a serious ailment that negatively affects how an individual feels, acts and thinks. The disorder causes a loss of interest in activities an person once enjoyed as well as bringing feelings of sadness.
From the definition, depression sounds pretty straightforward: you’re feeling down so you should be prescribed medication to deal with the sadness, right? Wrong.
Most individuals suffering from depression don’t even know they’re depressed because the condition manifests in different ways in every individual. This is why treatment shouldn’t be a one-size-fits-all approach.
Depression is not a cold you can catch from someone else. This is why it is important that mental health professionals first consider each individual personally and work to understand them before looking at the symptoms and deciding on the treatment approach that would benefit the patient the most. By responding empathically to a patient and understanding them and why they present with their particular set of issues, a physician becomes better equipped to select a suitable treatment for each individual patient. Prescribing antidepressants and calling it a day is never enough, especially if one considers the fact that drugs only manage the symptoms and don’t address the root cause of the ailment.
Given that individuals may be suffering from depression brought on by different circumstances, say for instance, the loss of a spouse, never grieving for a sibling who died too young, not receiving affection from parents or even post-partum depression, tailoring a treatment program that can deal with their distinct set of concerns and issues is the most logical way to approach treatment.
Adopting a more nuanced position that incorporates a spectrum of clinical scenarios that each point to a particular set of interventions that can be used by mental health professionals on patients to achieve the best possible outcome would be a better way to treat depression, as well as other mental health conditions. Additionally, mental health professionals should also keep up with scientific advances in the field, as these advancements not only inform them of the usefulness of a particular treatment but also how it can best be applied.
Speaking of treatments for mental health conditions, a number of companies, including Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), are currently engaged in research to develop psychedelic-based medicines that could potentially revolutionize the way in which mental health disorders are currently being treated.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
